Q-omics provides the consensus-scored FRMD1 profile across patient tissues and cancer cell-line models. FRMD1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FRMD1 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, FRMD1 RNA expression shows 8,100 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, and KIRP as cancer lineages where FRMD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRMD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRMD1 survival associations across molecular data types. FRMD1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRMD1 RNA expression–survival associations across cancer types. High FRMD1 expression shows unfavorable associations in UVM, KICH, LIHC, DLBC and THCA, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FRMD1 RNA expression.
This table summarizes FRMD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for FRMD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRMD1 shows lower tumor expression in KIRP, COAD, KIRC, KICH, BRCA and THCA. The KIRP box plot shows higher FRMD1 RNA expression in normal versus tumor tissue (log2 FC = −2.410, t-test p < 0.001).
This table shows molecular features associated with FRMD1 in patient tissues and cancer cell lines. In patient samples, FRMD1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, FRMD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
